Cargando…

Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis

Atherosclerosis, a chronic vascular disease, leads to molecular events bound with interplaying processes of inflammation and coagulation. In the present study, fibronectin (FN), FN containing extra domain A (EDA-FN), frequency of occurrence, and relative amounts of soluble plasma FN-fibrin complexes...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemańska-Perek, Anna, Krzyżanowska-Gołąb, Dorota, Pupek, Małgorzata, Klimeczek, Piotr, Witkiewicz, Wojciech, Kątnik-Prastowska, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883272/
https://www.ncbi.nlm.nih.gov/pubmed/27022744
http://dx.doi.org/10.1007/s10753-016-0336-0
_version_ 1782434240051281920
author Lemańska-Perek, Anna
Krzyżanowska-Gołąb, Dorota
Pupek, Małgorzata
Klimeczek, Piotr
Witkiewicz, Wojciech
Kątnik-Prastowska, Iwona
author_facet Lemańska-Perek, Anna
Krzyżanowska-Gołąb, Dorota
Pupek, Małgorzata
Klimeczek, Piotr
Witkiewicz, Wojciech
Kątnik-Prastowska, Iwona
author_sort Lemańska-Perek, Anna
collection PubMed
description Atherosclerosis, a chronic vascular disease, leads to molecular events bound with interplaying processes of inflammation and coagulation. In the present study, fibronectin (FN), FN containing extra domain A (EDA-FN), frequency of occurrence, and relative amounts of soluble plasma FN-fibrin complexes were analyzed in 80 plasma samples of patients suspected of coronary artery disease based on clinical evaluation and changes in arteries found by computed tomographic coronary angiography. The study showed that in the plasma of the patients’ group with high risk of coronary artery disease EDA-FN concentration was significantly higher (3.5 ± 2.5 mg/L; P < 0.025) and the molecular FN-fibrin complexes of 1000 kDa and higher occurred more often than in the groups of patients with mild risk of coronary artery disease and the normal age-matched. The increased level of EDA-FN and occurrence of FN-fibrin complexes could have a potential diagnostic value in the diagnosis and management of patients with coronary artery disease.
format Online
Article
Text
id pubmed-4883272
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-48832722016-06-06 Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis Lemańska-Perek, Anna Krzyżanowska-Gołąb, Dorota Pupek, Małgorzata Klimeczek, Piotr Witkiewicz, Wojciech Kątnik-Prastowska, Iwona Inflammation Original Article Atherosclerosis, a chronic vascular disease, leads to molecular events bound with interplaying processes of inflammation and coagulation. In the present study, fibronectin (FN), FN containing extra domain A (EDA-FN), frequency of occurrence, and relative amounts of soluble plasma FN-fibrin complexes were analyzed in 80 plasma samples of patients suspected of coronary artery disease based on clinical evaluation and changes in arteries found by computed tomographic coronary angiography. The study showed that in the plasma of the patients’ group with high risk of coronary artery disease EDA-FN concentration was significantly higher (3.5 ± 2.5 mg/L; P < 0.025) and the molecular FN-fibrin complexes of 1000 kDa and higher occurred more often than in the groups of patients with mild risk of coronary artery disease and the normal age-matched. The increased level of EDA-FN and occurrence of FN-fibrin complexes could have a potential diagnostic value in the diagnosis and management of patients with coronary artery disease. Springer US 2016-03-29 2016 /pmc/articles/PMC4883272/ /pubmed/27022744 http://dx.doi.org/10.1007/s10753-016-0336-0 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Lemańska-Perek, Anna
Krzyżanowska-Gołąb, Dorota
Pupek, Małgorzata
Klimeczek, Piotr
Witkiewicz, Wojciech
Kątnik-Prastowska, Iwona
Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis
title Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis
title_full Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis
title_fullStr Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis
title_full_unstemmed Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis
title_short Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis
title_sort analysis of soluble molecular fibronectin-fibrin complexes and eda-fibronectin concentration in plasma of patients with atherosclerosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883272/
https://www.ncbi.nlm.nih.gov/pubmed/27022744
http://dx.doi.org/10.1007/s10753-016-0336-0
work_keys_str_mv AT lemanskaperekanna analysisofsolublemolecularfibronectinfibrincomplexesandedafibronectinconcentrationinplasmaofpatientswithatherosclerosis
AT krzyzanowskagołabdorota analysisofsolublemolecularfibronectinfibrincomplexesandedafibronectinconcentrationinplasmaofpatientswithatherosclerosis
AT pupekmałgorzata analysisofsolublemolecularfibronectinfibrincomplexesandedafibronectinconcentrationinplasmaofpatientswithatherosclerosis
AT klimeczekpiotr analysisofsolublemolecularfibronectinfibrincomplexesandedafibronectinconcentrationinplasmaofpatientswithatherosclerosis
AT witkiewiczwojciech analysisofsolublemolecularfibronectinfibrincomplexesandedafibronectinconcentrationinplasmaofpatientswithatherosclerosis
AT katnikprastowskaiwona analysisofsolublemolecularfibronectinfibrincomplexesandedafibronectinconcentrationinplasmaofpatientswithatherosclerosis